{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-23-000094","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2023-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.581477+00:00","generated_at":"2026-06-14T11:25:18.172302+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Emergent gets $120M U.S. government order for smallpox vaccine ACAM2000, plus $60.6M for VIGIV","bullets":["ASPR exercises third annual option under 10-year, ~$2B contract; $120M for ACAM2000 doses due by June 30, 2023.","Separate contract option for VIGIV (smallpox treatment) valued at approximately $60.6M also secured.","Order follows prior NOIPs for ACAM2000, VIGIV, and BAT; strengthens U.S. Strategic National Stockpile.","Volume is smaller than prior years but supports Emergent's 2023 financial outlook and domestic manufacturing.","SVP Paul Williams highlights importance of public-private partnerships in biodefense preparedness."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-23-000094","json":"https://secwatch.observer/filing/0001367644-23-000094.json","markdown":"https://secwatch.observer/filing/0001367644-23-000094.md","text":"https://secwatch.observer/filing/0001367644-23-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000094/0001367644-23-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000094/ebs-20230526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T11:25:18.172302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c942807852c6320ae3537edbdc303773895914f7","claim":"Emergent BioSolutions Inc. amended Third Option Exercise with Office of the Assistant Secretary for Preparedness and Response (ASPR), an agency of the U.S. Department of Health and Human Services (HHS) valued at approximately $120 million (effective 2023-05-26).","evidence_excerpt":"On May 26, 2023, Emergent BioSolutions Inc. (including its wholly-owned subsidiaries, “Emergent”), through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a contract modification from the Office of the Assistant Secretary for Preparedness and Response (“ASPR”), an agency of the U.S. Department of Health and Human Services (“HHS”), exercising and funding the third of nine annual contract term extension options (the “Third Option Exercise”) for Emergent to supply ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) into the U.S. Strategic National Stockpile (the “SNS”). The Third Option Exercise is valued at approximately $120 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000094/0001367644-23-000094-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Office of the Assistant Secretary for Preparedness and Response (ASPR), an agency of the U.S. Department of Health and Human Services (HHS)"},{"label":"Value","value":"approximately $120 million"},{"label":"Effective","value":"2023-05-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}